CN113662857B - Drug storage system and method - Google Patents
Drug storage system and method Download PDFInfo
- Publication number
- CN113662857B CN113662857B CN202110986251.1A CN202110986251A CN113662857B CN 113662857 B CN113662857 B CN 113662857B CN 202110986251 A CN202110986251 A CN 202110986251A CN 113662857 B CN113662857 B CN 113662857B
- Authority
- CN
- China
- Prior art keywords
- composition
- patient
- taking
- storage system
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 318
- 229940079593 drug Drugs 0.000 title claims abstract description 75
- 238000003860 storage Methods 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 91
- 208000030963 borderline personality disease Diseases 0.000 claims abstract description 41
- 239000000284 extract Substances 0.000 claims description 64
- 230000006399 behavior Effects 0.000 claims description 38
- 229960004170 clozapine Drugs 0.000 claims description 34
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 34
- 230000008569 process Effects 0.000 claims description 25
- 238000012544 monitoring process Methods 0.000 claims description 21
- 230000009471 action Effects 0.000 claims description 19
- 238000012795 verification Methods 0.000 claims description 8
- 238000003745 diagnosis Methods 0.000 claims description 5
- 230000036962 time dependent Effects 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 3
- 238000012549 training Methods 0.000 claims description 3
- 230000002596 correlated effect Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 210000002249 digestive system Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 210000005036 nerve Anatomy 0.000 description 9
- 238000007789 sealing Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 208000022821 personality disease Diseases 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 206010067484 Adverse reaction Diseases 0.000 description 7
- 206010047700 Vomiting Diseases 0.000 description 7
- 230000006838 adverse reaction Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 230000008451 emotion Effects 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 230000008673 vomiting Effects 0.000 description 6
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 description 5
- 206010000117 Abnormal behaviour Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 240000004371 Panax ginseng Species 0.000 description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 description 5
- 206010039897 Sedation Diseases 0.000 description 5
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000036280 sedation Effects 0.000 description 5
- 229930002966 sinomenine Natural products 0.000 description 5
- 235000007516 Chrysanthemum Nutrition 0.000 description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 208000034507 Haematemesis Diseases 0.000 description 4
- 241000234435 Lilium Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 230000033764 rhythmic process Effects 0.000 description 4
- 229960001534 risperidone Drugs 0.000 description 4
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010026749 Mania Diseases 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 240000004980 Rheum officinale Species 0.000 description 3
- 235000008081 Rheum officinale Nutrition 0.000 description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 3
- 241000220317 Rosa Species 0.000 description 3
- 229940127236 atypical antipsychotics Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000036630 mental development Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 240000009138 Curcuma zedoaria Species 0.000 description 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 241000305491 Gastrodia elata Species 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 240000002948 Ophiopogon intermedius Species 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000008035 nerve activity Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000001020 rhythmical effect Effects 0.000 description 2
- 230000004799 sedative–hypnotic effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000010681 turmeric oil Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000019509 white turmeric Nutrition 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 244000001632 Acorus gramineus Species 0.000 description 1
- 235000013073 Acorus gramineus Nutrition 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 241000489492 Arisaema Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 240000008537 Burchellia bubalina Species 0.000 description 1
- 235000004415 Burchellia bubalina Nutrition 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 108010034145 Helminth Proteins Proteins 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010021567 Impulsive behaviour Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000157352 Uncaria Species 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZALMZWWJQXBYQA-UHFFFAOYSA-N [N].[Cl] Chemical compound [N].[Cl] ZALMZWWJQXBYQA-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000037086 body physiology Effects 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 230000009001 hormonal pathway Effects 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000152 swallowing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
- A61J7/0481—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers working on a schedule basis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
- A61J7/0418—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with electronic history memory
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
- A61J7/0427—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with direct interaction with a dispensing or delivery system
- A61J7/0436—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with direct interaction with a dispensing or delivery system resulting from removing a drug from, or opening, a container
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
- A61J7/0454—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers for dispensing of multiple drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2200/00—General characteristics or adaptations
- A61J2200/30—Compliance analysis for taking medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2200/00—General characteristics or adaptations
- A61J2200/70—Device provided with specific sensor or indicating means
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a drug storage system and a method, comprising a drug for treating borderline personality disorder and a storage device for storing the drug. The medicament for borderline personality disorder consists of two compositions: the time constitutes the first composition of the critical conditions of administration and the dosage constitutes the second composition of the critical conditions of administration.
Description
Technical Field
The invention relates to the field of medical machinery, in particular to a medicine storage system and a medicine storage method.
Background
Mood-labile personality disorders are also known as borderline personality disorder (Borderline Personality Disorder, BPD for short). Borderline personality disorder is a common personality disorder in psychiatric department, characterized mainly by instability of emotion, interpersonal relationship, self-image, behavior, and accompanying multiple impulsive behaviors, and is a complex and serious mental disorder. Typical features of borderline personality disorder are described by the learner as "stable unstable" and often manifest as therapeutic non-compliance and great difficulty in treatment. Clinical patients may show anxiety, depression, fear, and may also have "allergic hallucinations" and "delusions of allergic relationship". In the category of traditional Chinese medicine, borderline personality disorder is mostly "epilepsy" and "mania". The occurrence of borderline personality disorder is considered to be closely related to the "blood storage" and the "qi and blood stagnation" by the traditional Chinese medicine, so that brain qi and viscera qi are not connected. Clozapine, which is a representative of second generation antipsychotics (Second Generation Antipsychotics, SGAs), has a good auxiliary effect on the treatment of personality disorders, can directly inhibit the ascending activation system of the brainstem network, and has a powerful sedative-hypnotic effect. In the course of clozapine administration, other antagonisms of the body system are caused during sedation or hypnosis of the human body due to the blocking effect of neurotransmitters, thereby causing side effects such as headache, emesis, etc. during sedation or after sedation. Thus, many researchers now aim at traditional medicine. The therapeutic concept of traditional medicine is becoming accepted worldwide. In the aspect of psychiatry, more and more researchers adopt the combination of traditional Chinese medicine and western medicine to treat borderline personality disorder, and better curative effect is obtained.
The Chinese patent with publication number of CN105031513A discloses a medicament for treating borderline personality disorder in traditional Chinese medicine, which is prepared by combining the following traditional Chinese medicines in parts by mass: 10 parts of uncaria, 10 parts of white peony root, 3 parts of buffalo horn, 10 parts of moutan bark, 15 parts of sea-ear shell, 10 parts of dried rehmannia root, 10 parts of pinellia tuber, 10 parts of arisaema cum bile, 10 parts of baikal skullcap root, 10 parts of grassleaf sweetflag rhizome, 10 parts of radix curcumae, 10 parts of twotooth achyranthes root, 10 parts of tabasheer, 10 parts of medlar, 8 parts of chrysanthemum, 10 parts of dogwood and 7 parts of liquorice. The composition realizes the relief or treatment of borderline personality disorder by drug proportioning based on the traditional Chinese medicine principle of six meridians of human body, but the effect is proved by experiments. Further, based on that borderline personality disorder and schizophrenia have a certain abnormality in neurotransmitter direction, chinese patent publication No. CN106237268B discloses a pharmaceutical composition for treating schizophrenia, and the adverse reaction refers to constipation, dry mouth, weight gain, and the pharmaceutical composition is composed of the following raw materials: 2.5ml of zedoary turmeric oil, 1000g of red paeony root, 1000g of raw rhubarb and risperidone; 2.5ml of zedoary turmeric oil, 1000g of red paeony root and 1000g of raw rhubarb are prepared into 1000 tablets of Daying tablets, 8-10 tablets each time, 3 times a day; risperidone doses were gradually added starting at 1mg/d and increasing to 2-4mg/d over 1 week. The composition takes risperidone as a nerve blocking agent and is assisted with traditional Chinese medicine components to relieve adverse reactions generated in the nerve blocking process. For the side effects of nerve block, it is more caused by the collision of psychological and physical other hormone regulating pathways after the administration of the drug by the patient with abnormal neurotransmitter recognition, so that the traditional Chinese medicine composition for adverse reaction can be designed from the direction of regulating abnormal secretion of human hormone to radically relieve the adverse reaction. Due to the different properties of medicinal materials in different seasons and the different physical characteristics of human bodies, the medicine taking is carried out by matching, so that the medicine property can be maximally activated and the optimal medicine matching degree of the human body can be achieved, the medicine matching degree is also described in the 'spleen and stomach theory' of Lidong chong, and the 'must first year of life, the' must first year of life 'and the' must first time of the 'must be the first time of the' and the 'must first year of the' are the most obvious. And the following steps: and when no violations exist, no fellow is caused. And the following steps: no generation of qi. This is also common. "literature indicates the importance of time of a throttle or time representative to the progress of medication administration. Because the error rate of self-taking medicine of the borderline personality disorder patient is high and the traditional Chinese medicine taking components of different orders are different when the borderline personality disorder patient is nursing outside the hospital, a device for correctly taking medicine for the borderline personality disorder patient needs to be configured for storing the medicine composition taking the orders as the taking intervals.
Furthermore, there are differences in one aspect due to understanding to those skilled in the art; on the other hand, as the inventors studied numerous documents and patents while the present invention was made, the text is not limited to details and contents of all that are listed, but it is by no means the present invention does not have these prior art features, the present invention has all the prior art features, and the applicant remains in the background art to which the rights of the related prior art are added.
Disclosure of Invention
In view of the shortcomings of the prior art, the present invention contemplates a drug storage system comprising a drug for treating borderline personality disorder and a storage device for storing the drug. The medicament for borderline personality disorder consists of two compositions: the time constitutes the first composition of the critical conditions of administration and the dosage constitutes the second composition of the critical conditions of administration. Patients with borderline personality disorder lack self-management ability at least in a specific period of time, and cannot evaluate and predict self-behavior by themselves; their treatment depends not only on pharmacological measures but also on behavioral management. While personal mood management disorders by such patient caregivers due to long-term care often constitute a critical issue in such patient care. Although the use of intelligent devices with "no emotion, no emotional feedback" to assist in therapy has been a common technical measure, the lack of interest in learning such devices by patients and families has not gained popularity, even with extreme objections. In view of this, the present invention focuses on the taking measures that the patient and caretaker must face, taking special equipment to develop specific taking habits of the patient and not being affected by "emotional" fluctuations. By means of the administration training of the first and second compositions, in which the two pharmaceutical effects are mutually promoted and the administration conditions are mutually conditional, the individual patients can be better treated and the behavioral characteristics optimized. For this purpose, the administration schemes of two kinds of compositions which are mutually restricted in time and strictly required in dosage are specially selected, a compromise scheme is found between complex and accurate behavior treatment, and the two kinds of compositions can be approved and used by most patients through extensive tests. Although the first composition and the second composition need to be strictly adhered to for a specific time to achieve the optimal therapeutic effect, the composition used in the present invention does not have serious treatment accidents if the patient can take the second composition in an accurate dosage under the condition that the administration condition between the first composition and the second composition is not achieved. The first composition of the present invention is, for example, a traditional Chinese medicine preparation familiar to elderly patients (such patients are often elderly people), so that the administration mode of the first composition is significantly different from that of the second composition (such as tablets), and particularly, the administration mode of the first composition is significantly required to drink more liquid due to a large amount of operations, so that the image acquisition mode is sufficient to distinguish the behaviors of the two. Therefore, the medicine storage system does not need a large amount of high-precision data analysis and behavior pattern recognition, does not need complex and expensive biological sensors, and is particularly suitable for families of mental patients with extremely high disease-induced lean rate.
The prescribed dosage of the second composition is provided by the drug storage system in a time-dependent manner, and the drug storage system stores and processes the administration information in an image acquisition manner that is related to the time of the provision of the second composition. The first composition comprises at least four components whose times constitute critical conditions of administration and whose respective times of administration are different from each other, wherein the prescribed times of administration of the respective components in the first composition are specified by the drug storage system in a manner correlated with the time of administration of the second composition. The drug storage system stores and processes administration information of the respective components of the first composition in relation to the time of provision of the second composition in an image acquisition manner.
Preferably, the second composition can be clozapine. The first composition can be a traditional Chinese medicine extract, wherein the traditional Chinese medicine extract comprises: the preparation method comprises the steps of a first traditional Chinese medicine extract, a second traditional Chinese medicine extract, a third traditional Chinese medicine extract and a fourth traditional Chinese medicine extract. The first traditional Chinese medicine extract is used for taking in spring and comprises 5-10 parts of radix curcumae, 2-3 parts of agilawood, 1-2 parts of lily and 5-10 parts of radix salviae miltiorrhizae. The second traditional Chinese medicine extract is used for summer administration and comprises 5-10 parts of radix curcumae, 2-3 parts of agilawood, 15-30 parts of radix ophiopogonis, 5-15 parts of rose and 5-12 parts of chrysanthemum. The third traditional Chinese medicine extract is used for autumn administration and comprises 5-10 parts of radix curcumae, 2-3 parts of agilawood, 55-105 parts of radix astragali and 10-20 parts of rhizoma gastrodiae. The fourth traditional Chinese medicine extract is used for being taken in winter and comprises 5-10 parts of radix curcumae, 2-3 parts of agilawood, 5-10 parts of ginseng and 10-15 parts of rheum officinale. The critical dosing condition time can be bounded by a time schedule. The time of taking in spring can be the time interval from free standing spring to summer. The summer intake time can be a time period from free-standing summer to autumn. The administration time in autumn can be the time interval from free-standing autumn to standing winter. The time taken in winter can be the time interval from free-standing winter to spring.
The technical proposal has the advantages that: clozapine tablet formulation against 5-hydroxytryptamine (5-HT) 2 A) Receptors and Dopamine (DA) 1 ) The receptor has strong blocking effect on Dopamine (DA) 4 ) The receptor also has a blocking effect, can directly inhibit the ascending activation system of the brain stem reticular structure, and has strong sedative hypnotic effect. Clozapine can be inhibited by the transmission process to the neural network to achieve control of higher neural activity. With a decrease in nerve activity by clozapine, other immune or hormonal pathways of the body can be based on physiological responses that combat aberrant neural activity, thereby producing discomfort. Unlike other psychotherapeutic medicine, such as risperidone, clozapine can cause motor nerve spasm of tissue easily when being used for treating marginal personality disorder by blocking neurotransmitter movement, thereby causing headache, gastric strength contraction and other problems, and causing adverse reactions such as vomiting, headache and the like. By assisting the traditional Chinese medicine composition in relieving the stress of the human body with the stagnation of qi and blood caused by taking clozapine in the process of taking medicine, the sensitivity of motor nerves and sensory nerves in various tissues is reduced, and physiological reactions such as headache, vomiting and the like are inhibited. Furthermore, the Chinese medicinal composition in the form of extract can store the effective components in the Chinese medicament to the greatest extent. The extract can achieve the slow release process of the medicinal components in the absorption process, namely the process of achieving the peak plasma concentration in 3.2 hours along with the action of the clozapine, and the extract type Chinese medicinal composition can continuously keep the action on the human body with relatively stable medicine absorptivity, so as to relieve adverse reactions such as vomiting hiccup, dyspnea caused by the reduction of the nerve activity of the human body, head wind evil invasion and the like through pharmacological reaction on the human body. Because the traditional Chinese medicine has special priority in the process of growing, picking and taking, especially has different borderline personality disorder syndromes in different seasons or times, the traditional Chinese medicine composition suitable for standing spring, summer, autumn and winter is adopted to relieve adverse reaction symptoms in the process of treating borderline personality disorder. Note that, mood-unstable personality disorder is also called borderline personality disorder.
The medicine storage system judges the medicine taking sequence of a patient through image acquisition, and the medicine taking sequence is appointed through selectively opening the sealing cover of the medicine box for storing clozapine or opening the sealing cover of the medicine box for storing Chinese medicine extract. The first composition and the second composition of the drug constituting the borderline personality disorder are stored in the drug storage system in such a manner as not to intersect each other, wherein the drug storage system stores information related to the administration timing of "the first composition constituting the key administration condition in time" and "the second composition constituting the key administration condition in dose" at least in such a manner as to image-capture, such that the administration timing of the first composition and the second composition stored in such a manner as not to intersect each other is stored in relation to the administration behavior and can be subjected to time-dependent analysis.
According to a preferred embodiment, the drug storage system is adapted to take the first composition and the second composition sequentially in time by reminding the patient and/or his caretaker so that the respective patients take the first composition and the second composition for the purpose of enhancing the efficacy of each other. Preferably, the medicine for treating borderline personality disorder can comprise 0.5-2 parts of clozapine and 80.5-98 parts of traditional Chinese medicine extract.
The technical proposal has the advantages that: based on rational pharmacological responses, clozapine was used to inhibit various subclasses of borderline personality disorder by a major mechanism comprising the inhibition of 5-hydroxytryptamine (5-HT 2 A) Receptors and Dopamine (DA) 1 ) Blocking of the receptor. The traditional Chinese medicine composition matched with clozapine can comprise radix curcumae suitable for being taken in all seasons, and used for activating blood, relieving pain, promoting qi circulation, resolving stagnation, clearing heart fire, cooling blood, promoting bile flow, removing jaundice, radix curcumae used for activating qi, relieving pain, warming middle energizer, relieving vomiting, absorbing qi, relieving asthma, and sinomenine for sedation and analgesia, meanwhile, based on the difference of the running centers of gravity of the five viscera and six fu organs of the four-time body, a first traditional Chinese medicine extract suitable for spring is arranged, the first traditional Chinese medicine extract comprises radix curcumae and lignum aquilariae, and further comprises lily and radix salviae miltiorrhizae suitable for spring, wherein the lily is used for yin deficiency, dry cough, cough blood, dysphoria, insomnia, dreaminess and absentmindedness; radix Salviae Miltiorrhizae is used for treating chest pain, pain in chest, abdomen, hypochondrium, abdominal mass, pain due to pyretic arthralgia, vexation, and vexationSleep, irregular menstruation, amenorrhea, sore and swelling. The second traditional Chinese medicine extract is suitable for summer, and comprises radix curcumae and agilawood, and further comprises dwarf lilyturf tuber, rose flowers and chrysanthemum suitable for summer, wherein the dwarf lilyturf tuber is used for dry cough, pulmonary abscess, yin deficiency and fatigue cough, body fluid impairment and thirst, diabetes, vexation and insomnia, throat pain, constipation due to intestinal dryness and hematemesis and epistaxis due to blood heat; flos Rosae Multiflorae is used for treating summer heat hematemesis, thirst, dysentery, malaria, and incised wound hemorrhage; flos Chrysanthemi is used for treating wind-heat type common cold, headache, dizziness, conjunctival congestion, dim eyesight, sore, carbuncle and toxic swelling. The third traditional Chinese medicine extract is suitable for autumn, and comprises radix curcumae and agilawood, and also comprises astragalus membranaceus and gastrodia elata suitable for autumn, wherein the astragalus membranaceus is used for tonifying qi, consolidating exterior, expelling toxin, expelling pus, promoting urination and promoting granulation. Can be used for treating qi deficiency, debilitation, rectocele, spontaneous perspiration, edema, uterine prolapse, chronic nephritis, albuminuria, diabetes, and long-term open sore; gastrodia elata is used for calming endogenous wind and relieving spasm, suppressing liver yang, dispelling wind and dredging collaterals. The fourth traditional Chinese medicine extract is suitable for winter, and comprises radix curcumae and agilawood, and ginseng and rheum officinale suitable for winter, wherein the ginseng is used for tonifying qi, promoting the production of body fluid, quenching thirst and treating cough and hematemesis, thirst and stomach deficiency and vomiting; the rhubarb is used for purging heat toxin, removing food retention, removing blood stasis, treating constipation due to excessive heat, delirium, distention and fullness in the chest, early stage of diarrhea, tenesmus, stasis and amenorrhea, obstruction of the stomach, epidemic febrile disease during the time, red and painful eyes, hematemesis, epistaxis, yellow yang, edema, stranguria with turbid urine, carbuncle, sore and swelling, furuncle, soup fire injury, purging heat, removing heat from the intestines, cooling blood, removing toxin, removing stasis and dredging channels, and is used for treating constipation due to excessive heat, abdominal pain due to food retention, diarrhea and dysentery with uncomfortable jaundice due to damp-heat. The balance of yin and yang of the human body under different solar terms is regulated, so that the side effects caused by listlessness and the like which cannot be resisted due to weak body physiology such as vomiting and headache are relieved under the condition of not damaging the root.
The action of the drugs on the body is a periodic rhythm of time, called time pharmacodynamics. Since biological rhythms are associated with diseases, there are significant periodic rhythmic changes in the onset, symptomatic relief, or exacerbation of many diseases, and also in the effects of drugs, the concentrations and sensitivities of many drugs at target sites may also exhibit circadian rhythmic differences, resulting in differences in chronopharmacodynamics, including drug dose-responsive circadian rhythms; drug dose-circadian rhythm of blood concentration; the concentration-circadian rhythm of the drug, and the time pharmacology of the drug delivery system should be considered in the preparation of the dosage regimen to achieve drug safety and efficacy. At present, for the administration of chronodrugs in the theory of traditional Chinese medicine, research and discovery are carried out by modern technical means and are considered in the preparation of medication schemes. The human body channels are from the time of going away the gallbladder channel, the time of ugly going away the liver channel, the time of going away the lung channel, the time of the mortise going away the large intestine channel, the time of the day going away the stomach channel, the time of the spent going away the spleen channel, the time of the noon going away the heart channel, the time of the application going away the urinary bladder channel, the time of the unitary going away the kidney channel, the time of the five times of the time going away the heart channel and the time of the helminth going away the triple energizer, so that different time and different regions have certain influence on the traditional Chinese medicine taking, for example, the time of the spent going away the spleen channel is ordered, and the effect of promoting absorption by adjusting spleen transportation function by taking ginseng at the moment is optimal. In the pharmacokinetic study, the same dosage of sinomenine is given, and the concentration of sinomenine in plasma and brain is obviously higher than that of sinomenine in mortise and tenon time. Correspondingly, when the four ends are in the fourth state (5 points to 7 points) -the large intestine is in the vigorous state. Large intestine vermicular at the time of mortise and expelling toxin dregs; the lung is exterior-interior-related to the large intestine. The lung spreads enough fresh blood over the whole body, and then the large intestine is promoted to enter an excited state, and the processes of absorbing water and nutrition in food and discharging dregs are completed, so that sinomenine for metabolism and sedation can reach the maximum peak value of human medicine in mortise and tenon time. Based on the above, the Chinese medicinal extract can be taken at the time of mortise or time of past or at the node between the mortise and the time of past.
According to a preferred embodiment, clozapine and the herbal extract may be taken orally, wherein the herbal extract is taken earlier than clozapine. The Chinese medicinal extract and clozapine can be respectively placed in different compartments in the storage process to ensure the purity and correct administration of the medicines.
The technical proposal has the advantages that: the clozapine and the traditional Chinese medicine extract are not easily affected by factors such as external pH value and the like during digestion and absorption, but the clozapine and the traditional Chinese medicine extract are used for smoothing the nerve reflex in the body and avoiding the abnormality and disorder of information transmission paths such as hormone and the like, and can be better than the clozapine to enter the human body, so that the human body can relax nerves preferentially based on the absorption of the components of the traditional Chinese medicine composition, and the clozapine does not fight against nerves between tissues when entering the human body. The Chinese medicinal extract is in a viscous and formable state, and is daily wrapped with medicinal paper in the form of pill, and the medicinal paper is torn off during administration. Because the hardness, shape and storage modes of the traditional Chinese medicine extract and the clozapine tablet have obvious differences. When the traditional Chinese medicine extract and the clozapine are horizontally placed in the same space, the traditional Chinese medicine extract can influence the clozapine tablet based on factors such as smell, otherwise, the high hardness of the clozapine tablet can generate impact on the soft traditional Chinese medicine extract, so that the traditional Chinese medicine extract is deformed and even separated from the medicine paper, thereby causing bidirectional pollution.
According to a preferred embodiment, the storage device for storing the medicament comprises a central small medicine box and an expansion small medicine box, wherein the expansion small medicine box can form an expansion storage space of the central small medicine box based on connectors arranged on four walls of the central small medicine box.
The technical proposal has the advantages that: patients suffering from mental diseases, especially borderline personality disorder, need to take medicines autonomously according to medical orders during home maintenance or out-of-hospital maintenance, and the medicine types can comprise at least two types, particularly the medicine composition for borderline personality disorder relates to different oral orders at different times, and has disorder for patients to take medicines. The present invention relates to a storage device for storing a pharmaceutical composition for treating borderline personality disorder as referred to in the present invention. The device can be provided with an independent storage space of clozapine and an independent storage space of traditional Chinese medicine extractum corresponding to four types. The patient can take the medicines according to the medicine taking sequence, and the normal behavior training of the borderline personality disorder patient is realized based on the behavior monitoring of the medicine taking process of the patient by the device, so that the medicine taking process is based on the data of the patient condition judgment of the main doctor.
According to a preferred embodiment, the medicament storage device according to claim 9 is used for storing medicaments according to any one of claims 1 to 8, so that the medicaments are effectively stored, and cross-contamination between medicaments is avoided.
Drawings
FIG. 1 is a flow chart of one embodiment of the present invention;
FIG. 2 is a block diagram of one embodiment of the present invention;
fig. 3 is a schematic structural view of the present invention.
List of reference numerals
100: a center small medicine box; 200: expanding a small medicine box; 300: a third party connection unit; 310: a center position; 320: expanding the position.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.
Example 1
For the purpose of stably treating borderline personality disorder, the invention designs a pharmaceutical composition for treating borderline personality disorder, which comprises the following components: clozapine tablet 0.5g, cerebroprotein hydrolysate 0.06g (representative of nootropic agent or brain metabolism promoting agent) and Chinese medicinal extract 82g. The first traditional Chinese medicine extract taken in spring comprises 31.5g of radix curcumae, 12.6g of agilawood, 6.3g of lily and 31.5g of radix salviae miltiorrhizae. The second traditional Chinese medicine extract taken in summer comprises 12.8g of radix curcumae, 5.2g of agilawood, 38.4g of radix ophiopogonis, 12.8g of rose and 12.8g of chrysanthemum. The third Chinese medicinal extract taken in autumn comprises radix Curcumae 5.7g, lignum Aquilariae Resinatum 2.3g, radix astragali 62.6g and rhizoma Gastrodiae 11.4g. The fourth traditional Chinese medicine extract taken in winter comprises 18.6g of radix curcumae, 7.5g of agilawood, 18.6g of ginseng and 37.3g of rheum officinale. Taking spring, summer, autumn and winter as time limit, and selectively taking the first, second, third and fourth Chinese medicinal extracts according to four seasons. The extract exists in the form of pill, and the medicine paper is wrapped outside.
Example 2
A flow chart of one embodiment of the smart kit of the present invention is shown in fig. 1. After receiving a patient who has abnormal behavior in a hospital and distributing the patient who has abnormal behavior to a psychiatric/neurology medical staff, the medical staff can diagnose the patient's condition. Under the condition that the patient keeps clinical manifestations of dysphoria, fantasy and/or mania, medical staff with data read-write equipment carries out cognitive impairment judgment on the patient through the data read-write equipment so as to carry out disease diagnosis on the patient serving as an intelligent medicine box user; configuring a smart kit for the patient (which may include drug administration and drug administration information) by a healthcare worker from the diagnostic results analyzed and determined by the data reading and writing device; when a patient takes medicine by using the intelligent medicine box, the intelligent medicine box generates verification information related to medicine taking information by collecting operation behaviors of the patient on the intelligent medicine box and temporarily storing the operation behaviors in the intelligent medicine box according to a time-related mode. For example, the verification information generated by the smart kit may be generated based on patient taking behavior data obtained by monitoring patient taking behavior, which may be read by a data reading device at the doctor, so that the doctor may obtain patient taking behavior data and verification information related to the medication taking information. After obtaining the patient taking behavior data and the verification information related to the medicine taking information, a doctor can know the current mental state of the patient by combining the clinical manifestation of the current re-diagnosis of the patient and the mental evaluation result of the second time, so that the disease progress degree of the patient is judged.
According to a preferred embodiment, in case the patient is diagnosed with mood-labile personality disorder, the medical staff configures the intelligent kit with configuration information comprising: patient expected behavior, medication intake information. The medication information can be used to trigger the intelligent kit to play a prompt voice or instruction for the purpose of directing the patient to take the clozapine and the Chinese medicinal extract correctly. The expected patient behavior is that medical staff carries out data setting to the behavior that current patient is possible to show in advance according to past patient behavior data, and when the patient uses intelligent medicine box or carries out the action of taking medicine, the intelligent medicine box monitors patient behavior data and reaches the warning instruction of triggering when certain coincidence with preset data, and the instruction can be sent to guardian terminal to carry patient review to guardian's suggestion through guardian terminal.
When the patient's condition is aggravated, the patient holding the patient monitoring unit performs abnormal operation to the smart medicine box for monitoring the patient's operation of the smart medicine box. The intelligent medicine box performs data collection on abnormal operation at least once in a sensing mode of pressure change, speed change, image shooting and the like, performs data matching on the collected data and abnormal behavior data preset by medical staff, and judges that the illness state of a patient is aggravated when the preset abnormal behavior data threshold value is reached. When the illness state of a patient is lightened, the intelligent medicine box can acquire data of normal medicine taking operation of the patient with the patient monitoring unit at least once in sensing modes such as pressure change, speed change, image shooting and the like, and when judging modes such as the correct rate of behavior data or the correct medicine taking times in the operation process accord with preset conditions of medical staff on the intelligent medicine box, the intelligent medicine box judges that the illness state of the patient is lightened. The intelligent medicine box triggers an instruction for sending a review prompt to a guardian terminal held by a guardian based on a judging result of patient disease state alleviation or aggravation.
According to a preferred embodiment, in the re-diagnosis process, a medical staff with a data reading device reads data from the intelligent medicine box and the patient monitoring unit, communicates with a guardian to obtain information feedback of the non-behavioural diseases of the patient, and performs disease diagnosis by combining the physiological examination, consciousness level or cognitive metric table results of the patient. Medical staff conduct behavior data export according to data summarization statistics so as to judge the illness state of the patient. The intelligent medicine box is subjected to medicine distribution and medicine taking information alternation again based on the judgment of the disease progress.
According to a preferred embodiment, after medical staff performs medicine distribution storage on the intelligent medicine box and finishes medicine taking setting, the intelligent medicine box receives medicine taking prompt instructions, simultaneously sends medicine taking prompts to a patient monitoring unit worn on the wrist or other close-fitting positions of a patient and a terminal of a guardian, a patient holding the patient monitoring unit approaches the intelligent medicine box within a certain range or touches the intelligent medicine box in response to the issued prompts, the intelligent medicine box selectively opens a sealing cover of a space containing medicine to be taken based on a received signal sent by the patient monitoring unit, the patient is allowed to take correct medicine under forward guidance, and the intelligent medicine box monitors the behavior of the patient in real time based on monitoring of the patient monitoring unit held by the patient and monitoring of self pressure and weight change and stores the patient in a data form in a storage area of the intelligent medicine box.
According to a preferred embodiment, the patient's medication intake can be monitored by a smart kit in the form of a captured image. In particular, when the patient ingests the first composition, the first composition can be provided as a pharmaceutical pack and taken after being decocted with water, as distinguished from the direct and water-swallowed administration of the second composition. The two distinct modes of administration can be based on and aligned with the uptake of a critical action by a patient when the first composition is administered and the uptake of a critical action by the second composition when the second composition is administered, e.g., the first composition is present as a decocted fluid and can be directly swallowed by the patient in the fluid form, the smart kit recognizes the uptake of the first composition by image uptake of the fluid form of the first composition or the direct swallowing action without the water intake action by the patient; the second composition is often present in a tablet form, and the smart kit can recognize the circular form of the second composition or the action of taking water by the patient and mixing the medicine taking action by image intake when the patient takes the second composition.
According to a preferred embodiment, the guardian's terminal receives, via the terminal, monitoring data of the patient's taking action, including the type of drug administration, the weight of drug administration and/or the state of the closure, in response to the issued prompt; if the patient does not interact with the intelligent medicine box under the prompt of a certain time, the intelligent medicine box sends an early warning to the guardian terminal.
According to a preferred embodiment, the medical staff reads the data and information of the storage area of the intelligent medicine box through the data reading device when the patient is in a doctor, and the data and information are used for judging the illness state of the patient.
Specifically, in the case that the patient is diagnosed with unstable mood personality disorder, the medical staff places the chlor-azar flat on the central small medicine box 100, and according to four-hour lines, distinguishes each row of expansion small medicine boxes 200, and places a type of traditional Chinese medicine extract for one-hour line administration on each expansion small medicine box 200 corresponding to one outer wall of the central small medicine box 100. The patient monitoring unit, the guardian terminal and the intelligent medicine box held by the patient form data connection through a mobile communication network and/or WiFi. At noon of the first day, a set program in the intelligent medicine box triggers an instruction, the intelligent medicine box sends out an oral prompt of traditional Chinese medicine to a patient monitoring unit held by a patient and a bound guardian terminal held by a guardian, the patient is attracted to be noted by the prompt of the patient monitoring unit, and the intelligent medicine box is operated based on voice guidance of the intelligent medicine box to take traditional Chinese medicine extractum for taking in time of day and time of day. After the Chinese medicinal extract is taken correctly, the intelligent medicine box detects the behavior and self-change of the patient. Based on the double judgment of the change of the intelligent medicine box and the correct medicine taking operation of the patient, the intelligent medicine box sends the information that the traditional Chinese medicine extract is taken to the guardian terminal bound by the guardian, and guides the patient to take medicine in the next step. The intelligent medicine box for taking the medicine entering the next stage selects positive guide or negative interference or both of the positive and negative guide or negative interference through the taking state of the patient of the traditional Chinese medicine extract of the previous stage, for example, informs the patient of the taking position and the number of the medicine at the next stage, plays interference music and records the taking behaviors of the patient. And after the patient finishes taking the clozapine in the second stage, sending a medicine taking completion notice to a guardian terminal bound with the guardian. The intelligent medicine box can last to patient's action of taking medicine to patient's patient monitoring unit that the patient held keeps away from intelligent medicine box to a certain distance.
According to a preferred embodiment, the patient monitoring unit can be in the form of a bracelet, necklace or monitoring device co-located with the patient. The patient monitoring unit can draw attention of the patient through voice, vibration or light and the like, so that the next medicine taking guidance is performed. Preferably, because the life space of the patient with the mood-unstable personality disorder is fixed in the maintenance process, the patient monitoring unit can carry out image shooting on behaviors before taking medicines and after taking medicines in a stage in the process of taking medicines for the camera shooting assembly with a prompt function, and image data for judging abnormal behaviors or normal behaviors is provided for the intelligent medicine box.
Example 3
The invention designs a medicine storage system, which comprises a center small medicine box 100 and an expansion small medicine box 200, wherein the expansion small medicine box 200 can form an expansion storage space of the center small medicine box 100 based on connectors arranged on four walls of the center small medicine box 100, as shown in fig. 3. The center cartridge 100 is used to store clozapine. The expansion mini-kit 200 is used for storing traditional Chinese medicine extractum. The expansion mini-cartridge 200 can be connected with the central mini-cartridge 100 through a third party connection unit 300. Preferably, the third party connection unit 300 can be an electromagnetic connector. The four walls of the center small medicine box 100 are respectively provided with a main connector, and one side of two opposite sides of the expansion small medicine box 200 is provided with a secondary connector, and one side of the expansion small medicine box 200 is provided with the main connector, wherein the main connector and the secondary connector can be adsorbed to each other under the electrified state of the center small medicine box 100 and the expansion small medicine box 200. The expansion mini-kit 200 is respectively arranged on four walls of the center mini-kit 100 based on classification of the first traditional Chinese medicine extract, the second traditional Chinese medicine extract, the third traditional Chinese medicine extract and the fourth traditional Chinese medicine extract. As shown in fig. 3, the center mini-cartridge 100 can be extended in a direction in which the extension mini-cartridges 200 are connected based on the adsorption of the extension mini-cartridges 200 to each other or the center mini-cartridge 100, forming a cross-shaped cartridge. The drug storage system can be named as an intelligent drug box.
According to a preferred embodiment, the third party connection unit 300 can also be a receiving box with a snap or suction connection at the bottom, as shown in fig. 2, the receiving box bottom being provided with at least one central location 310 and at least one expansion location 320. The center 310 is used to fix the center cartridge 100 and to signal the center cartridge 100 to the third party connection unit 300. The expansion site 320 is used for fixing the expansion mini drug box 200 and realizing signal connection with the third party connection unit 300, so that signal connection with the center mini drug box 100 is realized through the third party connection unit 300. The containment box is provided with a cover that can seal the central cartridge 100 and the expansion cartridge 200 that it contains. The center cartridge 100 and the expansion cartridge 200 are also provided with small covers corresponding to the spaces of their individual cartridges, respectively. The small sealing cover is controlled by a signal to realize automatic opening or closing.
According to a preferred embodiment, the third party connection unit 300 and/or the central cartridge 100 is provided with a sound and light source player. The sound player can broadcast a medication intake instruction voice, an alarm, or other guiding music. The light source player is used for flashing light sources with different colors or frequencies so as to prompt or guide medicine taking.
According to a preferred embodiment, the medicine box is provided with a GPS positioning system which can accurately regulate and control time based on longitude and latitude of a current patient and convert time of day based on the current time, so that traditional Chinese medicine administration is performed in accurate time of day and hour of day.
According to a preferred embodiment, the central cartridge 100 is provided with a control center. The control center is used for receiving signals, sending instructions and carrying out logic judgment. The control center is arranged in an open-lid order based on the individual closures arranged by the compartments. Based on abnormal emotion, such as mania, anxiety or absentmindedness, which may exist in patients with borderline personality disorder or other mental diseases, if the drug storage device is not controlled, the patients are highly likely to take other drugs by mistake or misorder the taking of the drugs when taking the drugs alone. The invention is provided with at least five medicines, which comprise clozapine, a first traditional Chinese medicine extract, a second traditional Chinese medicine extract, a third traditional Chinese medicine extract and a fourth traditional Chinese medicine extract. The chlorine nitrogen is placed flat inside the center pill case 100. The first, second, third and fourth Chinese medicinal extracts are respectively placed in different expansion small medicine boxes 200. Preferably, the expansion mini-cartridges 200 containing the first, second, third and fourth herbal extracts are placed in four directions of the center mini-cartridge 100, respectively, so that the cartridges form a linear cross-shape. Based on the fact that the center small medicine box 100 and the expansion small medicine box 200 are connected with the third-party connecting unit 300, the center small medicine box 100 and the expansion small medicine box 200 form a complete signal transmission path. The control center for guiding the patient to take the drug prompts the administration of the pharmaceutical composition based on the following logic:
1) The medical staff or the family members and other mental health staff place the chlorine and nitrogen in the central small medicine box 100 horizontally, place the first traditional Chinese medicine extract in the first row of the expansion small medicine boxes 200, and place the second traditional Chinese medicine extract in the second row of the expansion small medicine boxes 200. Placing the third Chinese medicinal extract in a third row of expansion small medicine boxes 200, and placing the fourth Chinese medicinal extract in a fourth row of expansion small medicine boxes 200;
2) Program setting of medicine taking prompt is performed through a terminal or a display provided to the third party connection unit 300 and/or the center small medicine box 100;
3) In the set time and season, the third party connection unit 300 and/or the central small medicine box 100 gives out voice or alarm to draw the attention of the patient, and switches the voice when the whole sensing medicine box is taken (speed sensing or other sensing modes), so as to guide the patient to take the Chinese medicine extract;
4) The voice content can contain the content such as the position of the expansion small medicine box 200 where the Chinese medicine extract to be taken is located, the number of taken particles and the like, at the moment, the small sealing cover of an independent compartment for accommodating the medicine to be taken in the expansion small medicine box 200 can be opened, the small sealing covers of other positions are all in a state of being incapable of being opened, and the device can sense the specific position of the small sealing cover which is tried to be opened by a patient and store data until the small sealing cover of the medicine accommodating compartment to be taken in the expansion small medicine box 200 is opened;
5) The patient takes the medicine, the weight of the medicine in the compartment changes so as to activate the control system to send a command for guiding the playing in the next step, and the independent small cover of the center small medicine box 100 can be opened;
6) The patient opens the small cover of the center small medicine box 100 based on voice prompt, takes medicine, records the behavior data of the patient to take medicine after the small cover is opened, and sends an instruction to prompt the patient to close the cover arranged by the third party connection unit 300 by voice broadcast;
7) The whole process is completed without errors, and the control center sends instruction to play completion instructions and plays voices or music and the like to improve the achievement feeling of the patient;
8) The control center can store the action process of taking medicine by the patient in a certain period of time, the content can comprise the position and time selected by the cover opening and the weight selected by the medicine, and the data content is allowed to be copied or transferred to other storage terminals.
According to a preferred embodiment, when the combination drug clozapine and the traditional Chinese medicine extract are placed in the medicine box, the bottom logic or the most basic logic of the medicine box is that at set time and hour, one or more small covers of the expansion medicine box containing the traditional Chinese medicine extract are firstly and only opened, and other covers cannot be opened when being closed. After the patient taking logic judgment is performed by photographing the behavior of the patient and/or the gravity change in the expansion medicine box 200 and the opened expansion medicine box is pressed and closed, the central medicine box 100 for placing the clozapine can be automatically opened, so that at least the first traditional Chinese medicine extract/the second traditional Chinese medicine extract/the third traditional Chinese medicine extract/the fourth traditional Chinese medicine extract can be preferentially taken, and the clozapine can not be taken by the patient.
One of the advantages of the device is the controllability of the taking process of the patient. The fundamental features of borderline personality disorder are interpersonal relationship, self-image and emotional instability and significant impulsivity. Because of unstable character and violent impulsive emotion, uncontrollable mistaking and multi-taking medicines are easy to occur in the process of taking medicines. Based on the control center, the opening and closing control of the small covers of different small medicine boxes is performed, so that a patient taking medicine is guided to take medicine orally according to prompts such as voice and light. The device is an intelligent medicine box, and a control center can receive signals from a gravity sensor, a pressure sensor, a voice player and the like. Based on the gravity change of the medicine, the opening and closing change of the small sealing cover and the connection condition between the small medicine boxes, the control center can record and analyze the data change, so that the judgment of the next instruction is carried out.
The second advantage of the device is that the normal degree of the patient's behaviour can be monitored by the administration operation, i.e. the patient's actions in taking and taking the medicament according to the guidance can interact with the device to a certain extent, so that the device can collect patient behavioural data. In the interaction process, the device can reduce or increase the medicine taking difficulty of the user by giving positive feedback such as voice, music and the like or negative feedback such as information interference and the like to the user. Ways of information interference include giving error information in the guide information, playing dissonance tones or ambient noise, increasing ambient complexity or operational complexity, etc.
A third advantage of the present apparatus is that the guardian provides a review time node. Because patients with mental diseases are easy to repeat and the emotion accumulation points of the patients are easy to trigger under special scenes or conditions, the mental development of the patients is positive or negative, and the mental development cannot be clearly known to guardians. The taking action is a stable and continuous action node, and the disease progress analysis of the patient can be carried out through action judgment under the condition of not stimulating the patient. The intelligent medicine box can judge the forward or reverse development of the current mental state of the patient based on the information collection of the medicine taking behavior of the patient and the matching of the normal behavior data of the past data experience of medical staff. Further, when the process of mental development triggers the threshold set by medical staff, the intelligent medicine box sends a review prompt to the guardian terminal bound to the guardian, so that the patient can be ensured to be correctly treated by the medical treatment at the correct time node, and the situation that the mental deterioration of the patient is not found to cause disease deterioration or the mental is forward developed but excessive medicine is still taken to cause reverse emotion is prevented.
According to a preferred embodiment, the first column of expansion mini-cartridges 200 can correspond to green lights. The second column of expansion mini-cartridges 200 can correspond to red lights. The third column of expansion mini-cartridges 200 can correspond to yellow lights. The fourth row of expansion mini-boxes 200 can correspond to milky white lights. The patient is reminded in four seasons through different colors, and judged forward guiding information is increased. Further, under the forward guiding action of the lamplight, the voice prompt can be an error information prompt so as to increase the complexity of information processing, and the voice prompt is used for increasing the difficulty of taking medicine of a patient when the illness state of the patient is further stabilized.
Further, the device can record and log into a database based on the behavior of the mental patients such as passive medication of borderline personality disorder. The physician can interpret the health outcome by behavioral recording data in combination with individual physiological indicators to form digital biomarkers to assist the physician in the subsequent care of the patient.
It should be noted that the above-described embodiments are exemplary, and that a person skilled in the art, in light of the present disclosure, may devise various solutions that fall within the scope of the present disclosure and fall within the scope of the present disclosure. It should be understood by those skilled in the art that the present description and drawings are illustrative and not limiting to the claims. The scope of the invention is defined by the claims and their equivalents.
Claims (7)
1. A drug storage system for a drug for treating borderline personality disorder comprising a drug for treating borderline personality disorder and a storage device for storing the drug, characterized in that the drug for treating borderline personality disorder is comprised of two compositions: a first composition with time forming a critical taking condition and a second composition with dosage forming a critical taking condition, wherein the first composition is a traditional Chinese medicine extract, the second composition is clozapine, the taking mode of the first composition is different from that of the second composition, and the first composition plays a role in behavior training or treatment in time conditions;
The medical staff configures the storage device of the patient according to the diagnosis result analyzed and determined by the data reading and writing equipment; when a patient takes medicine by using the storage device, the storage device generates verification information related to medicine taking information by collecting operation behaviors of the patient on the storage device and temporarily storing the operation behaviors of the patient in the storage device according to a time-related mode, the verification information is generated based on patient taking behavior data obtained by monitoring the patient taking behavior, and the verification information can be read by a data reading device at a doctor, so that the doctor can obtain the patient taking behavior data and the verification information related to the medicine taking information;
the first composition and the second composition of the drugs constituting the borderline personality disorder are stored in the drug storage system without intersecting each other, wherein the drug storage system stores information related to the administration timing of the first composition of the time-critical administration condition and the second composition of the dose-critical administration condition in at least an image acquisition manner such that the administration timing of the first composition and the second composition stored without intersecting each other is stored in association with the administration behavior and is capable of performing a time-dependent analysis;
The medicine taking of the patient can be monitored by the storage device in a mode of taking images, and two significantly different taking modes can be distinguished by taking and comparing the critical actions of the patient when the first composition is taken and the critical actions of the patient when the second composition is taken based on the storage device;
the first composition includes at least four components whose times constitute critical conditions of administration and whose respective times of administration are different from each other, wherein the prescribed times of administration of the respective components in the first composition are specified by the drug storage system in a manner correlated with the time of presentation of the second composition.
2. The drug storage system of claim 1, wherein the ordered dosage of the second composition is provided by the drug storage system in a time dependent manner and wherein the drug storage system stores and processes the administration information in an image acquisition manner related to the time of the provision of the second composition.
3. The drug storage system of claim 1, wherein the drug storage system stores and processes administration information associated with the time of delivery of the second composition for respective ones of the first compositions in an image acquisition manner.
4. The drug storage system of claim 1, wherein the first composition of drugs comprising the borderline personality disorder is administered preferentially in a sequential manner specified by the drug storage system.
5. The drug storage system of claim 1, wherein the first and second compositions of drugs comprising the borderline personality disorder are ingested in a manner that enters the digestive system.
6. The drug storage system of claim 1, wherein one of four compositions of the first composition of drugs comprising the borderline personality disorder is capable of being disposed outside of the second composition in the form of a slow release layer.
7. A drug storage system according to claim 1, wherein the drug storage system is adapted to take the first and second compositions sequentially in time by reminding the patient and/or their caretaker so that the respective patients take the first and second compositions for the purpose of enhancing the efficacy of each other.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110986251.1A CN113662857B (en) | 2021-08-25 | 2021-08-25 | Drug storage system and method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110986251.1A CN113662857B (en) | 2021-08-25 | 2021-08-25 | Drug storage system and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113662857A CN113662857A (en) | 2021-11-19 |
| CN113662857B true CN113662857B (en) | 2024-04-05 |
Family
ID=78546614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110986251.1A Active CN113662857B (en) | 2021-08-25 | 2021-08-25 | Drug storage system and method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113662857B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113662858B (en) * | 2021-08-25 | 2024-03-29 | 首都医科大学宣武医院 | Intelligent medicine taking prompt system and method |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084828A (en) * | 1989-09-29 | 1992-01-28 | Healthtech Services Corp. | Interactive medication delivery system |
| CN201642854U (en) * | 2010-02-04 | 2010-11-24 | 何伊仁 | Electronic medicine box |
| CN105662850A (en) * | 2016-01-11 | 2016-06-15 | 上海云樱医疗科技有限公司 | Intelligent medicine box equipment and medicine taking management method |
| CN205672239U (en) * | 2016-03-07 | 2016-11-09 | 坦通自动化（上海）有限公司 | A kind of family expenses drug control device and intelligence control system thereof |
| CN106420347A (en) * | 2016-11-15 | 2017-02-22 | 新疆医科大学第附属医院 | Method for improving medication compliance of patient and intelligent medicine box system |
| CN106580708A (en) * | 2015-10-19 | 2017-04-26 | 北京超思电子技术有限责任公司 | Medicine taking prompting device and medicine taking prompting system |
| CN107308003A (en) * | 2017-06-07 | 2017-11-03 | 深圳市南山区慢性病防治院 | A kind of novel intelligent medicine box for carrying User logs in interface |
| CN107890422A (en) * | 2017-10-16 | 2018-04-10 | 深圳市南山区慢性病防治院 | A kind of novel intelligent medicine box of supervision and management chronic medication |
| CN108743371A (en) * | 2018-06-01 | 2018-11-06 | 武汉大学人民医院（湖北省人民医院） | One kind can share intelligent medicine box system and its application process |
| CN110711139A (en) * | 2019-11-13 | 2020-01-21 | 王峰 | Intelligent medicine box and intelligent medicine taking control system and method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101016438B1 (en) * | 2008-09-10 | 2011-02-21 | 한국전자통신연구원 | Apparatus for supporting medication and Method for supporting medication in the apparatus |
| US10383794B2 (en) * | 2013-10-23 | 2019-08-20 | Nexpil, Inc. | Medication compliance alert device |
-
2021
- 2021-08-25 CN CN202110986251.1A patent/CN113662857B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084828A (en) * | 1989-09-29 | 1992-01-28 | Healthtech Services Corp. | Interactive medication delivery system |
| CN201642854U (en) * | 2010-02-04 | 2010-11-24 | 何伊仁 | Electronic medicine box |
| CN106580708A (en) * | 2015-10-19 | 2017-04-26 | 北京超思电子技术有限责任公司 | Medicine taking prompting device and medicine taking prompting system |
| CN105662850A (en) * | 2016-01-11 | 2016-06-15 | 上海云樱医疗科技有限公司 | Intelligent medicine box equipment and medicine taking management method |
| CN205672239U (en) * | 2016-03-07 | 2016-11-09 | 坦通自动化（上海）有限公司 | A kind of family expenses drug control device and intelligence control system thereof |
| CN106420347A (en) * | 2016-11-15 | 2017-02-22 | 新疆医科大学第附属医院 | Method for improving medication compliance of patient and intelligent medicine box system |
| CN107308003A (en) * | 2017-06-07 | 2017-11-03 | 深圳市南山区慢性病防治院 | A kind of novel intelligent medicine box for carrying User logs in interface |
| CN107890422A (en) * | 2017-10-16 | 2018-04-10 | 深圳市南山区慢性病防治院 | A kind of novel intelligent medicine box of supervision and management chronic medication |
| CN108743371A (en) * | 2018-06-01 | 2018-11-06 | 武汉大学人民医院（湖北省人民医院） | One kind can share intelligent medicine box system and its application process |
| CN110711139A (en) * | 2019-11-13 | 2020-01-21 | 王峰 | Intelligent medicine box and intelligent medicine taking control system and method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113662857A (en) | 2021-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500991A (en) | Life maintenance mode, brain suppression and personal health information platform | |
| Blows | The biological basis of mental health | |
| Murray | Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research | |
| Shahrokh et al. | The language of mental health: A glossary of psychiatric terms | |
| CN101926950B (en) | Brain-invigorating traditional Chinese medicine composite and preparation method and detection method thereof | |
| CN101670055A (en) | Traditional Chinese medicine composition for treating disease of pyelonephritis and preparation method | |
| Doenlen et al. | Electrical activity in rat cortico-limbic structures after single or repeated administration of lipopolysaccharide or staphylococcal enterotoxin B | |
| CN101444611A (en) | Traditional Chinese medicine composition for treating lumbocrural pain and lumbar intervertebral disc protrusion and preparation method thereof | |
| CN113662857B (en) | Drug storage system and method | |
| CN108159382A (en) | A kind of medicine of insomnia with anxiety-depression | |
| CN103536757B (en) | Traditional Chinese medicine composition having effects of tonifying kidney, replenishing essence, tonifying qi, nourishing blood and consolidating basis, and preparation method and application thereof | |
| Talbot et al. | Motor neuron disease | |
| Simonsen et al. | Illustrated pharmacology for nurses | |
| CN101095900B (en) | Sichuan chrysanthemum pain-relieving capsule and method for preparing the same | |
| CN111658735A (en) | Intelligent system plaster for conditioning physique and preventing and treating various gastrointestinal diseases and preparation method | |
| CN108578667A (en) | A kind of drug that treating methamphetamine abstinence syndrome and its application | |
| CN104368073A (en) | Sleep conditioning method | |
| CN112569237B (en) | Application of combination or compound of imatinib and derivatives thereof and nicotine or analogues thereof in preventing and treating nicotine addiction and relapse | |
| CN103169847A (en) | Traditional Chinese medicine extraction pill for treating deficiency of kidney-essence and impotence and premature ejaculation and preparation method thereof | |
| CN100479835C (en) | Compound medicine for treating diarrheal irritable bowl syndrome | |
| CN113689931B (en) | Auxiliary system and method for taking medicine | |
| CN114344388B (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| Ahn et al. | A literature analysis on medicinal use and research of cannabis in the Meiji Era of Japan | |
| CN116920052B (en) | Traditional Chinese medicine composition for treating primary sicca syndrome with depression and preparation method and application thereof | |
| CN107375600A (en) | A kind of Chinese medicine composition for treating qi stagnation and blood stasis type coronary heart disease and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |